Intended for UK Healthcare Professionals. This website contains promotional content.
Intended for IE Healthcare Professionals. This website contains promotional content.
Report adverse events

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page.

  1. Home >
  2. Medicines >
  3. Guidelines

The EASL 2020 recommendations

Below is a summary of the 2020 EASL recommendations for retreatment after patients experience failure on DAA treatments.1

EASL recommendations

Adapted from EASL.1 Please refer to individual SmPCs prior to prescribing2,3 

 

EPCLUSA® (sofosbuvir and velpatasvir 400 mg/100 mg tablets) 

 

Prescribing Information

 

EPCLUSA® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older.

You may also like to visit

Safety Profile

Abbreviations:

DAA = direct-acting antiviral; EASL = European Association for the Study of the Liver; NS5A = nonstructural protein 5A; RAS = resistance-associated substitution; SVR = sustained virologic response.

References:

  1. European Association for the Study of the Liver (EASL). J Hepatol. 2020;73:1170–1218.
  2. VOSEVI® Summary of Product Characteristics.
  3. EPCLUSA® Summary of Product Characteristics.

UK-VSV-0090

Date of preparation July 2024